Citigroup’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-26,600
| Closed | -$90K | – | 7963 |
|
|
2018
Q3 | $90K | Sell |
26,600
-18,300
| -41% | -$66K | ﹤0.01% | 6016 |
|
|
2018
Q2 | $169K | Sell |
44,900
-15,700
| -26% | -$76.4K | ﹤0.01% | 5232 |
|
|
2018
Q1 | $248K | Sell |
60,600
-2,300
| -4% | -$10.7K | ﹤0.01% | 4740 |
|
|
2017
Q4 | $292K | Buy |
62,900
+31,800
| +102% | +$175K | ﹤0.01% | 4675 |
|
|
2017
Q3 | $221K | Buy |
31,100
+9,000
| +41% | +$64.7K | ﹤0.01% | 4914 |
|
|
2017
Q2 | $160K | Buy |
22,100
+4,500
| +26% | +$28.1K | ﹤0.01% | 4970 |
|
|
2017
Q1 | $108K | Sell |
17,600
-17,700
| -50% | -$97K | ﹤0.01% | 5153 |
|
|
2016
Q4 | $207K | Sell |
35,300
-12,400
| -26% | -$67.8K | ﹤0.01% | 5249 |
|
|
2016
Q3 | $253K | Buy |
47,700
+12,400
| +35% | +$66.9K | ﹤0.01% | 4476 |
|
|
2016
Q2 | $234K | Sell |
35,300
-26,700
| -43% | -$149K | ﹤0.01% | 4349 |
|
|
2016
Q1 | $290K | Buy |
62,000
+18,700
| +43% | +$74.6K | ﹤0.01% | 4733 |
|
|
2015
Q4 | $219K | Sell |
43,300
-1,300
| -3% | -$6.18K | ﹤0.01% | 4664 |
|
|
2015
Q3 | $157K | Buy |
44,600
+21,500
| +93% | +$144K | ﹤0.01% | 4688 |
|
|
2015
Q2 | $231K | Buy |
+23,100
| New | +$248K | ﹤0.01% | 4329 |
|
Citigroup's KERX Position: Q4 2018 in Review
Citigroup sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 232,013 shares — an estimated $789K sold.
Citigroup first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $789K in Q3 2018. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Citigroup reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Citigroup sold 232,013 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $789K.
- Citigroup first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Citigroup's Keryx Biopharmaceuticals Inc position peaked at $789K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Citigroup's 13F filing for Q4 2018, filed 12 Feb 2019.